

23 ET 24 NOVEMBRE 2023

19^{èmes} Journées Daniel Dargent

de Chirurgie Gynécologique,
Cancérologique et Mammaire

Centre de Congrès de Lyon
Cité Internationale
50 quai Charles de Gaulle
69463 Lyon Cedex 06



Rétention de grossesse: hystéroscopie ou aspiration?

Pr Cyrille HUCHON

Hôpitaux Lariboisière et Saint-Louis

Université Paris Cité



**Université
Paris Cité**



Conflits d'Intérêts



GEDEON RICHTER

AstraZeneca 



*Pharma
Mar* 

NORDIC
PHARMA 

INTRODUCTION

➤ Rétention persistante : risque d'adhérences

➤ Aspiration : 19% d'adhérences

- traumatisme endomètre sain
- laisse rétention

➤ Aspirations répétées : 40% d'adhérences

➤ [Hooker, Human Reproduction Update, 2013](#)


➤ Adhérences inflammatoires, fibrose : syndrome d'Asherman (aménorrhée, infertilité, tb placentation)


➤ Fertilité après FCS : 60% à 2 ans, 80% à 5 ans

➤ [Smith, BMJ, 2009](#)

➤ **alternative à l'aspiration (aveugle)**

➤ **hystéroscopie opératoire (visualisation cavité utérine)**







Hysteroscopic management of retained products of conception: meta-analysis and literature review



Noam Smorgick*, Oshri Barel, Noga Fuchs, Ido Ben-Ami, Moty Pansky, Zvi Vaknin

Departments of Obstetrics and Gynecology, Assaf Harofe Medical Center, Affiliated with the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel




Fig. 2. Forest plot comparison of subsequent pregnancies in women undergoing hysteroscopy versus curettage.

Des résultats discordants?



Long-term complications and reproductive outcome after the management of retained products of conception: a systematic review

Angelo B. Hooker, M.D.,^{a,b} Humeyra Aydin, M.D.,^b Hans A. M. Brölmann, M.D., Ph.D.,^b and Judith A. F. Huirne, M.D., Ph.D.^b

^a Department of Obstetrics and Gynaecology, Zaans Medisch Centrum, Zaandam; and ^b Department of Obstetrics and Gynaecology, VU University Medical Center, Amsterdam, the Netherlands

TABLE 2

Distribution of pregnancy preceding RPOC and the extent of IUAs.

Pregnancy preceding RPOC	HR (%)	D&C	P ^a
First or second trimester	23 (15.6)	10 (5.2)	< .0001
Delivery	71 (48.3)	140 (72.9)	< .01
Not reported	53 (36.1)	12 (6.1)	< .01
Total	147 (43.4)	192 (56.6)	
Clinical category of IUAs	HR (n = 141)	D&C (n = 189)	
Mild	10	21	NS
Moderate	5	29	< .001
Severe	3	6	NS
Total	18 (12.8)	56 (29.6)	< .001

^a Fisher's exact test.

Hooker. Long-term outcome after RPOC. *Fertil Steril* 2016.

TABLE 3

Characteristics of the studies reporting on reproductive outcome in women treated for RPOC.

Study	Design	Study period	Characteristics of the women	Follow-up, months	Treatment	Time to conception	Case no.	Conception rate (%)	Ongoing pregnancy/live birth rate	Miscarriage rate
Ben-Ami (2014)	Retro	2000–2010	RPOC after abortion or delivery, histological confirmed	NR	HR	7.4 (SD, 7)	83	77 (92.8)	67 (87.0)	16 (20.8)
							94	87 (92.6)	83 (95.4)	11 (12.6)
Golan (2011)	Retro	2001–2007	RPOC after medical TOP, D&C, or delivery.	36	HR	NR	28	23 (82.1)	21 (91.3)	1 (4.3)
Rein (2011)	Pros	2004–2007	RPOC after D&E for first- or second-trimester miscarriage or term delivery	24 (8–38)	HR	27 (7–39)	45	31 (68.9)	26 (83.9)	3 (9.7)
							37	22 (59.5)	19 (77.3)	3 (13.6)
Faivre (2009)	Pros	'96–'06	RPOC after spontaneous miscarriage, after D&E, medical TOP, or term delivery.	43 (23–69)	HR	NR	30	23 (76.7)	21 (91.3)	NR
Jimenez (2009)	Retro	'01–'08	RPOC after abortion or delivery	NR	HR	8.4 (SD, 7.1)	30	24 (80)	19 (62.5)	4 (16.7)
Cohen (2001)	Retro	'97–'00	RPOC after D&C or delivery	6 (6–42)	HR	7.3 (SD, 6.7)	17	14 (82.4)	13 (71.4)	1 (7.1)
							16	10 (62.5)	7 (70)	3 (30)
Total					D&C	11.0 (SD, 6.4)	380	311/380 (81.8)	278/380 (73.2)	42/350 (12)

Note: NR = not reported; Pros = prospective study; Retro = retrospective study.

Hooker. Long-term outcome after RPOC. *Fertil Steril* 2016.

Hysteroscopic morcellation vs. curettage for removal of retained products of conception: a multicenter randomized controlled trial

Liselot P. Wagenaar, M.D.,^a Tjalina W. Hamerlynck, M.D., Ph.D.,^{b,c} Celine M. Radder, M.D., Ph.D.,^d Louissette W. Peters, M.D.,^d Steven Weyers, M.D., Ph.D.,^{b,c} Benedictus C. Schoot, M.D., Ph.D.,^{a,b} and Huib A. van Vliet, M.D., Ph.D.^{a,b}

Postoperative course.^a

Primary outcome	HM (73)	EVA (80)	Difference (95% CI)
Postoperative complications			
Hemorrhage (>500 cc)	2 (2.7)	1 (1.3)	1.4 (−3.1 to 6) ^b
Other	0 (0)	1 (1.3)	
Rehospitalization	2 (3.1)	1 (1.5)	1.2 (−3.5 to 6.0) ^b
Second-look hysteroscopy performed	63 (86.3)	64 (80)	6.3 (−5.5 to 18.1) ^b
Completeness of removal at second-look hysteroscopy	60 (95.2)	52 (82.5)	−14 (−24.9 to −3.1) ^b
Additional treatment	8 (12.5)	21 (32.8)	−20.1 (−34.3 to −6) ^b
Operative hysteroscopy	8 (12.5)	21 (32.8)	
For RPOC	3 (4.7)	9 (14.1)	
For IUAs	6 (9.4)	13 (20.3)	
Vacuum curettage	1 (1.6)	0 (0)	
Laparoscopic repair	0 (0)	1 (1.6)	

CI = confident interval; EVA = electric vacuum aspiration; HM = hysteroscopic morcellation; IUAs = intrauterine adhesions; RPOC = retained products of conception.

^a Data are mean ± standard deviation, median (interquartile range [25%–75%]), or n (%) unless otherwise specified. Percentage excluded patients with missing values.

^b Absolute risk differences and 95% CIs were estimated.

Wagenaar. Hysteroscopic morcellation of RPOC: RCT. Fertil Steril 2023.

- Toutes rétentions..
- Curetage aspiratif immédiat vs Hystéro morcellateur à plus de 8 semaines...

TABLE 4

Primary outcome.^a

Primary outcome	HM (63) ^b	EVA (64) ^b	Difference (95% CI)	P value
Presence of IUAs ^c	9 (14.3)	13 (20.6)	−6 (−19.1 to 7.1) ^d	.348
Mild	4 (44.4)	3 (23.1)		
Moderate	3 (33.3)	6 (46.2)		
Severe	2 (22.2)	4 (30.8)		

CI = confident interval; EVA = electric vacuum aspiration; HM = hysteroscopic morcellation; IUAs = intrauterine adhesions.

^a Data are mean ± standard deviation, median (interquartile range [25%–75%]), or n (%) unless otherwise specified. Percentage excluded patients with missing values. All P values are from chi-square test unless otherwise specified.


^b The number of patients who underwent second-look procedure.

^c Presence of IUAs as diagnosed with second-look hysteroscopy after at least 1 menstruation or after a minimum period of 4 weeks after removal of the placental remnants.

^d Absolute risk differences and 95% CIs were estimated.

Wagenaar. Hysteroscopic morcellation of RPOC: RCT. Fertil Steril 2023.

Fertilité



European Journal of Obstetrics & Gynecology and Reproductive Biology 211 (2017) 98–102



ELSEVIER

Contents lists available at ScienceDirect

European Journal of Obstetrics & Gynecology and
Reproductive Biology

journal homepage: www.elsevier.com/locate/ejogrb



Full length article

Evaluation of fertility after operative hysteroscopy to remove retained products of conception

Louise Sonnier^{a,*}, Antoine Torre^a, Pauline Broux^a, Arnaud Fauconnier^{a,b},
Cyrille Huchon^{a,b}



Hypothèse

L'hystéroscopie opératoire serait une technique chirurgicale plus efficace et moins dangereuse que le curetage aspiratif intra-utérin pour le traitement des avortements spontanés incomplets

Huchon et al. *Trials* (2015) 16:363
DOI 10.1186/s13063-015-0900-1



STUDY PROTOCOL

Open Access

Operative hysteroscopy versus vacuum aspiration for incomplete spontaneous abortion (HY-PER): study protocol for a randomized controlled trial



Cyrille Huchon^{1,2*}, Martin Koskas^{2,3}, Aubert Agostini⁴, Cherif Akladios⁵, Souhail Alouini⁶, Estelle Bauville⁷, Nicolas Bourdel^{8,9}, Hervé Fernandez^{10,11,12}, Xavier Fritel¹³, Olivier Graesslin¹⁴, Guillaume Legendre¹⁵, Jean-Philippe Lucot¹⁶, Isabelle Matheron¹⁷, Pierre Panel¹⁸, Cyril Raiffort¹⁹ and Arnaud Fauconnier²²⁰

Critères d'inclusion

- Patiente majeure de moins de 45 ans, assurée sociale, présentant une rétention intra-utérine après avortement spontané incomplet du premier trimestre (<14 SA) d'une grossesse désirée.
- Rétention intra-utérine diagnostiquée à l'échographie pelvienne transvaginale retrouvant une image hétérogène ou un sac entre 15 et 50 mm d'épaisseur.
- Décision de prise en charge chirurgicale de l'avortement spontané incomplet par l'équipe soignante et la patiente.

Critères de non inclusion


- Patiente porteuse d'une malformation utérine connue.
- Patiente ayant déjà bénéficié d'un traitement chirurgical pour la rétention intra-utérine en cours.
- Patiente nécessitant un geste hémostatique en urgence pour métrorragies abondantes.
- Patiente porteuse d'un dispositif intra-utérin.
- Grossesse évolutive ou extra-utérine.
- Rétention intra-utérine consécutive à une IVG.
- Grossesse obtenue par assistance médicale à la procréation.


Design

- **Essai, multicentrique randomisé de suivi de deux bras de patientes traitées chirurgicalement pour un avortement spontané incomplet soit par curetage aspiratif, soit par hystéroscopie opératoire.**
- **Procédure de randomisation informatisée au bloc opératoire en simple aveugle pour la patiente**

Schéma de l'étude

Outcome= Take-home baby





Objectif principal d'HYPHER

Démontrer que le traitement chirurgical par hystéroscopie opératoire des rétentions après avortements spontanés incomplets permet d'augmenter la fertilité comparativement au curetage aspiratif.

Objectifs secondaires de l'étude

- **Comparer les délais d'obtention de grossesse entre les deux traitements**
- **Démontrer que l'hystéroscopie opératoire entraîne une diminution des complications per et postopératoires**
- **Démontrer que l'utilisation de l'hystéroscopie opératoire diminue le taux de réinterventions chirurgicales**

Critères de jugement

Principal:

Grossesses intra-utérines évolutives > 22 SA dans les deux ans après prise en charge.

Secondaires:

- Délai d'obtention de grossesse
- Fausses couches spontanées et grossesses extra-utérines dans le suivi des patientes
- Taux de complications chirurgicales selon la classification de Clavien-Dindo
- Réinterventions chirurgicales secondaires à la prise en charge de la rétention intra-utérine.

Grade	
1	Any deviation from the normal postoperative course without the need for pharmacological treatment or surgical, endoscopic and radiological interventions. Acceptable therapeutic regimens are: drugs as antiemetics, antipyretics, analgetics, diuretics and electrolytes and physiotherapy. This grade also includes wound infections opened at the bedside.
2	Requiring pharmacological treatment with drugs other than such allowed for grade I complications. Blood transfusions, antibiotics and total parenteral nutrition are also included.
3	Requiring surgical, endoscopic or radiological intervention
3a	Intervention under regional/local anesthesia
3b	Intervention under general anesthesia
4	Life-threatening complication requiring intensive care/intensive care unit management
4a	Single organ dysfunction
4b	Multi-organ dysfunction
5	Patient demise

Nombre de Sujets nécessaires

- En prenant un **taux de naissance vivante moyen à 2 ans de 60%**
- Hypothèse que **l'hystérocopie augmente d'au moins 20% ce taux**
- Puissance=80%; risque $\alpha=0,05$ (bilatéral),
- Inclusion de **260 patientes par bras.**
- **Estimation de 10% de perdues de vue,**
- Inclusion de **572 patientes** (286 par bras).



Research


JAMA | **Original Investigation**

Operative Hysteroscopy vs Vacuum Aspiration for Incomplete Spontaneous Abortion A Randomized Clinical Trial

Cyrille Huchon, MD, PhD; Hocine Drioueche, MSc; Martin Koskas, MD, PhD; Aubert Agostini, MD, PhD;
Estelle Bauville, MD; Nicolas Bourdel, MD, PhD; Hervé Fernandez, MD, PhD; Xavier Fritel, MD, PhD;
Olivier Graesslin, MD, PhD; Guillaume Legendre, MD, PhD; Jean-Philippe Lucot, MD; Pierre Panel, MD;
Cyril Raiffort, MD; Géraldine Giraudet, MD, PhD; Laurence Bussièrès, PhD; Arnaud Fauconnier, MD, PhD

FLOW CHART

Figure 1. Recruitment, Randomization, and Follow-up in the HY-PER Trial



^a Eleven participants were excluded after randomization and excluded from all further analyses (6 from the hysteroscopy group; 5 from the vacuum aspiration group).

^b According to the French law, participants who have withdrawn their consent cannot be included in the analysis.

^c The intention-to-treat analysis was performed according to the treatment group to which the patients were assigned at randomization, regardless of the procedure they received and the duration of their follow-up. Individuals denoted as *excluded* were not included in the intention-to-treat analysis.

^d The per-protocol analysis included all randomized patients except for those who did not receive the complete allocated surgery after randomization and the patients lost to follow-up.

^e The intention-to-treat population and per-protocol population were used to assess the primary outcome. The primary outcome was the occurrence of an intrauterine pregnancy with a duration beyond 22 weeks of gestation in the 2 years after the randomization.

PATIENTES

	Hystéroscopie N=282	Aspiration N=281
Age, années, (Moyenne, DS)	33,2 (5,4)	32,1 (5,4)
Gestité (Mediane, Min-Max)	2 (1-10)	2 (1-11)
Parité (Mediane, Min-Max)	1 (0-9)	1 (0-6)
ATCD FCS (%)	89 (32%)	98 (35%)
ATCD curetage , N (%)	36 (12,8%)	36 (12,8%)
Semaines d'aménorrhées, (Moyenne, DS)	11,4 (2,5)	11,8 (3,0)
Métrorragies, N(%)	151 (54%)	134 (48%)
Douleurs, N (%)	79 (28%)	84 (30%)
Epaisseur rétention, (Moyenne, DS)	30,3 (10,8)	29,3 (10,3)

Table 2. Outcomes at 2 Years for Included Randomized Patients^a

	No. (%)		Difference, % (95% CI)	P value
	Hysteroscopy (n = 282) ^b	Vacuum aspiration (n = 281) ^b		
Primary outcome^c				
Ongoing pregnancy lasting beyond wk 22 of gestation	177 (62.8)	190 (67.6)	-4.8 (-13.0 to 3.0) ^d	.23 ^e
Secondary outcomes				
Time to conception, median (IQR), mo	5.7 (2.8 to 11.0)	4.9 (3.2 to 9.5)	0.4 (-0.4 to 1.2) ^f	.40 ^g
Surgical reintervention to empty uterus	7 (2.5)	1 (0.4)	2.1 (0.3 to 4.5) ^d	.07 ^h
Subsequent miscarriage	47 (16.7)	36 (12.8)	3.9 (-2.0 to 9.7) ^d	.20 ^e
Subsequent ectopic pregnancy	3 (1.1)	4 (1.4)	-0.4 (-2.4 to 1.6) ^d	.72 ^h
Clavien-Dindo surgical complication grade ≥ 3 at surgery or during the 2-y follow-up ⁱ	10 (3.5)	9 (3.2)	0.3 (-2.7 to 3.5) ^d	.82 ^e
Other outcomes				
Duration of surgery, median (IQR) [No.], min	30.0 (20.0 to 45.0) [272]	11.5 (8.0 to 15.0) [270]	17.0 (15.0 to 20.0) ^f	<.001 ^g
Duration of hospitalization, median (IQR) [No.], d ^l	0.0 (0.0 to 0.0) [271]	0.0 (0.0 to 0.0) [266]	0.0 (0.0 to 0.0) ^f	.03 ^g
Duration of hospitalization ≥ 1 d, No./total (%) ^l	37/271 (13.7)	21/266 (7.9)	5.8 (0.5 to 11.1) ^d	.03 ^e

^a Among the 574 patients randomized, 11 patients were excluded postrandomization: 4 due to eligibility (1 excluded due to age >45 years, 1 due to pregnancy facilitated by in vitro fertilization, 1 due to expulsion before procedure, 1 due to retention after induced abortion) and 7 due to withdrawn consent according to the French law.

^b Indicates the number of patients except for categories in which another numeric value is reported.

^c Ongoing pregnancy of at least 22 weeks' duration during the 2-year follow-up. Ongoing pregnancies beginning during the 2-year follow-up but with a duration of less than 22 weeks of gestation by the end of the follow-up did not fulfill the primary outcome definition, even if a pregnancy that began during the follow-up resulted in a live birth after the 2-year follow-up period.

^d Absolute risk differences and 95% CIs were estimated using a generalized linear model.

^e Calculated using the χ^2 test.

^f Calculated using the Hodges-Lehmann confidence interval estimator for median differences.

^g Calculated using the Wilcoxon-Mann-Whitney test.


^h Calculated using the Fisher exact test.

ⁱ The Clavien-Dindo classification is a standardized grading system of surgical complications.¹⁷ Grade 1 is defined as any deviation from the normal postoperative course without the need for pharmacological treatment or surgical, endoscopic, or radiological interventions. Grade 2 is defined as complications requiring pharmacological treatment with drugs other than those permitted for grade 1 complications. Grade 3 is defined as surgical complications requiring surgical, endoscopic, or radiological intervention (3a without general anesthesia and 3b under general anesthesia). Grade 4 is defined as a life-threatening complication that requires management in a high dependency.

^l All patients were hospitalized in gynecologic departments, and no cases were managed in emergency departments. The majority of patients were hospitalized in day surgery. The number of days of hospitalization thus corresponds with the number of nights spent in hospital for the surgical management of the incomplete spontaneous abortion.

ANALYSE DE SURVIE ITT


Analyse de survie methode de KAPLAN-MEIER



HR: 0,87, 95% CI 0,71-1,07
P=0,18

ANALYSE DE SURVIE PERPROTOCOLE

Analyse de survie methode de KAPLAN-MEIER



HR: 0,85; 95% CI: 0,69-1,04
P=0,11

COMPLICATIONS

Table 3. Summary of Adverse Events at 2 Years for Included Randomized Patients^a

	No. (%)		Difference, % (95% CI)
	Hysteroscopy (n = 282) ^b	Vacuum aspiration (n = 281) ^b	
Intraoperative adverse events			
Failure of the planned procedure, No./total (%) ^c	19/278 (7)	0/281 (0)	6.8 (4.1 to 10.4) ^d
Uterine perforation	4 (1.4)	1 (0.4)	1.1 (-0.5 to 3.0) ^d
Hemorrhage ≥500 mL ^e	2 (0.7)	3 (1.1)	-0.4 (-2.4 to 1.6) ^d
Postoperative adverse events			
Intervention to treat uterine synechia	2 (0.7)	5 (1.8)	-1.1 (-3.4 to 1.0) ^d
Intervention for tubal infertility or adhesion	1 (0.4)	0	0.4 (-1.0 to 2.0) ^d

^a Among the 574 patients randomized, 11 patients were excluded postrandomization: 4 due to eligibility (1 excluded due to age >45 years, 1 due to pregnancy facilitated by in vitro fertilization, 1 due to expulsion before procedure, 1 due to retention after induced abortion) and 7 due to withdrawn consent according to the French law.

^b Indicates the number of patients except for categories in which another numeric value is reported.

^c Indicates procedure with conversion to a different procedure or failure.


^d Absolute risk difference and 95% CIs were estimated using a generalized linear model.

^e Hemorrhage was quantified using quantification of aspiration and/or a subgluteal bleeding collection bag.

ANALYSE RETENTION SANS SAC

ITT


Analyse de survie methode de KAPLAN-MEIER



	Curetage	Hystérectomie	p
Grossesse>22SA	70,4%	69,1%	0,88


PER PROTOCOLE

Analyse de survie methode de KAPLAN-MEIER



	Curetage	Hystérectomie	p
Grossesse>22SA	79,2%	76,6%	0,76

EFFET CENTRE?



AJUSTEMENT

ITT

	OR	IC 95%
Hystéroscopie	0,81	0,57-1,14
Age	0,9	0,86-0,93
Barrière antiadhérentielle	1,52	0,57-4,75
HSC diag	0,36	0,13-0,96

PER PROTOCOLE

	OR	IC 95%
Hystéroscopie	0,77	0,52-1,15
Age	0,87	0,84-0,91
Barrière antiadhérentielle	1,57	0,49-6,98
HSC diag	0,26	0,09-0,68

DISCUSSION

- ESSAI CHIRURGICAL Français RANDOMISE
- Inclusions et perdues de vue conforme aux prévisions
- Taux de grossesse attendu avec CJP « parlant » aux patientes
- ESSAI NEGATIF: Attention aux extrapolations de séries sans comparatifs: LAAC trial, LION study,...
- Aucun centre n'a de meilleur résultat avec l'hystérocopie.....
- Essai ne permettant pas d'évaluer les barrières antiadhérentielles et la place de l'hystérocopie diagnostique postopératoire



Conclusion

- L'hystérocopie opératoire n'est pas plus performante que le curetage aspiratif pour la prise en charge des avortements spontanés incomplets:
 - Pas plus de grossesses évolutives
 - Pas d'amélioration des délais d'obtention de grossesse
 - Pas de diminution des complications per et postopératoires
 - Pas de diminution du taux de réinterventions chirurgicales

- Merci à tous les centres participants!

